T1	intervention 10 39	aromatase inhibitor treatment
T2	total-participants 591 594	254
T3	eligibility 595 642	patients with ER-positive primary breast cancer
T4	intervention-participants 692 695	198
T5	control 700 724	no presurgical treatment
T6	control-participants 738 740	56
T7	outcome 1078 1109	baseline expression of 48 genes
T8	outcome 1559 1631	downregulation of genes involved in cell proliferation and ER signalling
T9	outcome 1646 1701	Signature scores of E2F activation and TP53 dysfunction
T10	outcome 1806 1829	degree of heterogeneity
T11	outcome 960 984	baseline ESR1 expression
